Endometrial Clear Cell Carcinomas with and without Aberrant p53 Expression: A Study of 16 Cases
Deborah DeLair, Robert A Soslow. Memorial Sloan-Kettering Cancer Center, New York, NY
Background: Clear cell carcinoma is a relatively rare tumor type which classically does not demonstrate a mutation in TP53 in ovarian examples. Endometrial serous carcinomas (EMSC) nearly always show these mutations, almost all of which correlate with overexpression (OE) of the protein or complete loss of expression (null phenotype) by immunohistochemistry (IHC). Little is known, however, about p53 expression in endometrial tumors with clear cell histology.
Design: Endometrial carcinomas which showed typical clear cell histology (EMCC), diffuse positivity with HNF-1β by IHC, and aberrant p53 expression (OE or null phenotype), also by IHC, were included. Mixed epithelial and morphologically ambiguous tumors were excluded. Clinical characteristics and immunohistochemical results for p16 (OE or not) and ER were also recorded. For comparison, EMCCs without aberrant p53 were also analyzed.
Results: Eight cases each of HNF-β-positive EMCC with and without aberrant p53 expression were identified. The clinical and immunohistochemical results are shown in the tables below.